WAVE Life Sciences (WVE) Stock Price, News & Analysis

Company Overview

WAVE Life Sciences Corporation is a clinical-stage biotechnology company dedicated to the development of stereopure oligonucleotide therapies that address underlying genetic drivers of disease. The company leverages a proprietary platform to design and manufacture single-isomer oligonucleotides with enhanced potency, specificity and durability. Its research and development efforts are focused on a range of neuromuscular, neurodegenerative and metabolic disorders with significant unmet medical need.

WAVE’s Precision Oligo™ chemistry platform enables the production of oligonucleotides with defined three-dimensional structures, which the company believes can improve tissue distribution and therapeutic indices relative to conventional oligos. Key programs in clinical development include treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), with additional preclinical efforts targeting Huntington’s disease, acute hepatic porphyria and other rare genetic conditions. WAVE has also entered strategic collaborations with major biopharmaceutical partners to accelerate discovery and development of oligonucleotide-based oncology and metabolic disease programs.

Founded in 2014 and headquartered in Cambridge, Massachusetts, WAVE Life Sciences operates complementary research facilities in the United Kingdom and maintains partnerships in Asia and Europe to support global development. The company’s leadership team combines expertise in oligonucleotide chemistry, clinical development and manufacturing scale-up, positioning WAVE to advance its pipeline through late-stage trials and regulatory filings. With a mission to translate cutting-edge oligonucleotide science into transformative therapies, WAVE continues to expand its platform capabilities and foster collaborations that broaden its therapeutic reach.

Key Stats

• Today's Range: $7.97 to $8.73
• 50-Day Range: $5.94 to $8.34
• 52-Week Range: $5.04 to $16.74
• Volume: 2.46 million shs
• Average Volume: 1.33 million shs
• Market Capitalization: $1.30 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.15
• Consensus Rating: Moderate Buy

WAVE Life Sciences Stock Analysis - MarketRank™

WAVE Life Sciences scored higher than 92% of companies evaluated by MarketBeat, and ranked 94th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

WAVE Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

WAVE Life Sciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for WAVE Life Sciences are expected to grow in the coming year, from ($1.14) to ($1.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of WAVE Life Sciences is -9.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of WAVE Life Sciences is -9.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

WAVE Life Sciences has a P/B Ratio of 6.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

73.25% of the float of WAVE Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

WAVE Life Sciences has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in WAVE Life Sciences has recently increased by 482.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

WAVE Life Sciences does not currently pay a dividend.

Dividend Growth

WAVE Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.58

Percentage of Shares Shorted

73.25% of the float of WAVE Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

WAVE Life Sciences has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in WAVE Life Sciences has recently increased by 482.19%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.65

News Sentiment

WAVE Life Sciences has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for WAVE Life Sciences this week, compared to 6 articles on an average week.

Search Interest

3 people have searched for WVE on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added WAVE Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, WAVE Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $208,500.00 in company stock.

Percentage Held by Insiders

23.98% of the stock of WAVE Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

89.73% of the stock of WAVE Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

WVE Stock Analysis - Frequently Asked Questions

How have WVE shares performed this year?

WAVE Life Sciences' stock was trading at $12.37 at the start of the year. Since then, WVE shares have decreased by 32.6% and is now trading at $8.34.

How were WAVE Life Sciences' earnings last quarter?

WAVE Life Sciences Ltd. (NASDAQ:WVE) posted its quarterly earnings results on Thursday, May, 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by $0.02. The firm had revenue of $9.18 million for the quarter, compared to analyst estimates of $11.65 million.
Read the conference call transcript.

How do I buy shares of WAVE Life Sciences?

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of WAVE Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that WAVE Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Intel (INTC) and Netflix (NFLX).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:WVE
• CIK: 1631574
• Web: www.wavelifesciences.com
• Phone: (656) 236-3388
• Fax: 617-949-2901
• Employees: 240
• Year Founded: N/A

Price Target and Rating

• Average Price Target for WAVE Life Sciences: $20.15
• High Price Target: $36.00
• Low Price Target: $10.00
• Potential Upside/Downside: +149.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$97.01 million
• Net Margins: N/A
• Pretax Margin: -107.04%
• Return on Equity: -86.49%
• Return on Assets: -37.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.95
• Quick Ratio: 2.95

Sales & Book Value

• Annual Sales: $108.30 million
• Price / Sales: 11.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.37 per share
• Price / Book: 5.89

Miscellaneous

• Outstanding Shares: 155,560,000
• Free Float: 118,259,000
• Market Cap: $1.26 billion
• Optionable: Optionable
• Beta: -1.01